MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease
The neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before sym...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Non-Coding RNA |
Subjects: | |
Online Access: | https://www.mdpi.com/2311-553X/7/1/8 |
id |
doaj-6c8e4056c1a14a139ce213a19696ff99 |
---|---|
record_format |
Article |
spelling |
doaj-6c8e4056c1a14a139ce213a19696ff992021-02-02T00:03:30ZengMDPI AGNon-Coding RNA2311-553X2021-02-0178810.3390/ncrna7010008MicroRNAs as Candidate Biomarkers for Alzheimer’s DiseaseColin Kanach0Jan K. Blusztajn1Andre Fischer2Ivana Delalle3Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Academic Medical Center, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USADepartment of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany Street, Boston, MA 02118, USAGerman Center for Neurodegenerative Diseases, Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, 37075 Göttingen, GermanyDepartment of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Academic Medical Center, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USAThe neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before symptoms manifest in order to provide early intervention. Surrogate markers are critical for early disease detection, stratification of patients in clinical trials, prediction of disease progression, evaluation of response to treatment, and also insight into pathomechanisms. Here, we review the evidence for a number of microRNAs that may serve as biomarkers with possible mechanistic insights into the AD pathophysiologic processes, years before the clinical manifestation of the disease.https://www.mdpi.com/2311-553X/7/1/8plasma microRNAomeMCIepigenetic dysregulation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Colin Kanach Jan K. Blusztajn Andre Fischer Ivana Delalle |
spellingShingle |
Colin Kanach Jan K. Blusztajn Andre Fischer Ivana Delalle MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease Non-Coding RNA plasma microRNAome MCI epigenetic dysregulation |
author_facet |
Colin Kanach Jan K. Blusztajn Andre Fischer Ivana Delalle |
author_sort |
Colin Kanach |
title |
MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease |
title_short |
MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease |
title_full |
MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease |
title_fullStr |
MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease |
title_full_unstemmed |
MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease |
title_sort |
micrornas as candidate biomarkers for alzheimer’s disease |
publisher |
MDPI AG |
series |
Non-Coding RNA |
issn |
2311-553X |
publishDate |
2021-02-01 |
description |
The neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before symptoms manifest in order to provide early intervention. Surrogate markers are critical for early disease detection, stratification of patients in clinical trials, prediction of disease progression, evaluation of response to treatment, and also insight into pathomechanisms. Here, we review the evidence for a number of microRNAs that may serve as biomarkers with possible mechanistic insights into the AD pathophysiologic processes, years before the clinical manifestation of the disease. |
topic |
plasma microRNAome MCI epigenetic dysregulation |
url |
https://www.mdpi.com/2311-553X/7/1/8 |
work_keys_str_mv |
AT colinkanach micrornasascandidatebiomarkersforalzheimersdisease AT jankblusztajn micrornasascandidatebiomarkersforalzheimersdisease AT andrefischer micrornasascandidatebiomarkersforalzheimersdisease AT ivanadelalle micrornasascandidatebiomarkersforalzheimersdisease |
_version_ |
1724314713034063872 |